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VOL. XIV JANUARY, 1947 NO.1 
THE Rh FACTOR IN HEMOLYTIC DISEASE 
OF THE NEWBORN 
DONALD H. KAPMP, M.D. 
Pathologist, P1·ovidence Hospital, Det7·oit, Michigan 
T HIS article is not intended as a comprehensive nor a critical review of the relationship of the Rh factor to hemolytic disease of the 
newborn, but rather as an introduction to the paper on the "Moral -
ity of the Rh factor" to be given by Father Schwitalla. In this paper 
. I will discuss the development of the work which has been done on the 
Rh factor of the blood in humans, discuss briefly its relationship in 
hemolytic disease of the newborn and indicate the value of Rh studies 
particularly in relationship to pregnancy. 
In their experiments during and just prior to 1937, Landsteiner lind 
Wiener produced an antibody in rabbits by the injection of monkey 
blood as an antigen. This new antibody not. only agglutinated the red 
blood cells of monkeys but in addition agglutinated those of cert.ain white 
humans. This indicated a new factOl" present in the red cells of certaill 
humans Hnd because it had been developed by the usc of the blood of the 
macacus rhesus monkey the name Rh was given it to indicate the original 
source of the antigen. Further st.udies indicated that approximately 
85% of whit.e humans possessed this Rh agglutinogen in their red cells 
and in the other 15% it was absent. They were accordingly designated 
as Rh posit.ive (containing the Rh agglutinogen) and Rh negative 
(an absence of the Rh agglutinogen). This newly described factor 
was not initially considered to be of great importance until in 1939 
\iViener and Peters found the antibody to this newly discovered Rh factor 
in three patients who had severe hemolytic reactions following trans-
fusions of otherwise compatible blood. These patients apparently had 
been immunized or better, iso-immunized, to the rhesus or Rh factor. 
Levine and his coworkers then noted the very frequent occurrence of 
2 THE LIN ACRE QUARTERLY 
transfusion reactions in women who had stillbirths or infa nt.s with erythro-
hlastosis fetalis . At. this time L evine postulate(f the vC'r), interesting 
theory t.hat. an Rh negat.ive mother who bea rs an Rh positive rictus 
beeallle sensitized in some manner to the Rh factor of t.he fetus and 
suhsequently developed antibodies in her bloo(f to the Rh factor. These 
Hntibodies in turn passed through t.he placenta a nd into the fetal blood 
circ ul ation with r esulting agglutina tion and hemolys is of the fetal blood . 
The intra-uterine hemolysis in the infant then would account for th(' 
sevC're symptoms which were found to be present in erythroblast.osis 
retali s. Because ery throhlastosi s fetali s in its varied forms was demon-
st.rated to be the r esult of fetal and neo-natal hemolysis it. is rcfelTC'd to 
I·oelay as helllolyt.ic diseasC' of infants and newborns . 
The ant.ibody produeed by t.ht, artificial ill1ll1uniuttion of rabbits to 
Ilion key hlooel has certain eharHcterist.ics which arc identical with that 
of the antibody produeed in wOI1lC'n delivC' ring infants wit.h helllolytic 
. disease. ThC' antihody pl'OducC'(f in huma ns has been des igna t ed ~lnti 
Itho a nel th t' erythl'Ocytes which arc agglutinated hy this antibo(fy an ' 
(lesignated as the Rho type. L ate r it. was found that there were two an(f 
perhaps llIore f acto r s present. in human iso-immunir.at ion which wer C' not 
p)"('sC'nt in the original immunization of rabbit s with 11l0nkey blood . 
The two a(fditional ant.ibodies which have been detected in human s 
arc givC'n the designations anti Rhl anel anti Rhll a nd accordingly, 
thesC' sC'm detect. the presence or absence of the cOl'l'esponding three 
H.h fador'" in hUlllan hlood , namely, Hh" Rhl and Rhll . By the usc 
of tlwse tin·C'e agglutinating sera we can thus differentiat.e eight. RII 
l.ypC's in the first. four of whieh the Rh" fador is ahsf'nt amI in t.he 
last. foul' is present, as follows: 
('Iinieally Rh negativt' 
Ith negative, Hh' , Hhl ' , Rhl Rh" 
( ~ Iinically Rh positivI' 
1{llo' Hit, (Rh"lI), Rh~ (Rholl), Rh, RIt~ 
in this sehenl(' tlw Hh, and Rh~ factors are considered to be cOlllbi-
lIations of the HII" and Rhll allel Rho l'C'spect.ivcly as Hit ,,' and llh,,]] . 
SillcC' t.he Hh" factor which cOlTesponos to the original anti-rhesus 
S( ' rUII I is by fal' the most alltigenic and therefore the lIIost illlport.ant 
clinically, it is the vresence 01' absence of this factor which is deter-
lIIined by I1IOSt. of the antiserullI on the cOl1lmercial lIIarket. For 
clinical p urposes we lIlay consider any blood in which t hr Rh" factor 
is preSt'nt. t.o be Rh positive an(f t.hose in which tilt' Rh" facto!· is 
absent. to \)(' Rh negative. This is true in approxilllately H,I) % of 
individuals while t.he rHl'r r Hh Factors account for only approxi -
lIIately 2% of the white pop ul ation. 
The presence 01' the absence of the Hh factor in the ~rythrocytes 
IS hereditaril y drtermin e(f Ilnd the Rh fac tor is t.rnnsmitteo to 
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offsllring as a Mendclian dominant by a llair of allelic gelles, Hh 
(dominant) and rh (rcccssive). Sincc cvcry individual posscsscs 
a pail' of genes from cvery allelic scries of gcncs onc from the 
father and onc frOIll t.he mothcr, thcrc arc thus thrce gPllot.ypes 
possible. 
TYPES 
Rh-
Rh+ 
Rh+ 
Rit .FA C TOR 'rltANsMISSIOI\ 
GENOTYPES 
rh rh 
Rh Rh 
Rh rh 
Homozygous 
Homozygous 
Heterozygous 
.l<'ronl this we can sec that fur the entire groull ot' eight Hh tYllcs, 
there are twcnty-onc llossiblc gcnatypes. Since thc typc of blood 
is determined by thc charactcr of thc blood of the parcnt and tl 
gene inherited froUl each of tltc father and the l1Iothcl', the Hit 
factor is inherited as in tlte following chart. 
INHJo: H,l'l' A I\ C]'; 0]0' THJo: Hit FA C TOH 
PARENT 
TYPE GENOTYPE 
Rh- rh rh 
Rh+ - Rh Rh 
Rh+ Rh rh 
Rh+ Rh Rh 
Rh+ Rh rh 
P ARENT 
TYPE GENOTYPE 
Rh-- rh rh 
Rh- rh rh 
Rh- rh rh 
Rh+ Rh Rh 
Rh+ Rh rh 
CHILl) 
TYPE GENOTYPE 
Rh- (100%) rh rh 
Rh+ (100%) Rh rh 
Rh+ ( 50%) Rh rh 
Rh+ (100%) Rh Rh 
Rh+ ( 25%) Rh Rh 
Rh + ( 50%) Rh rh 
Rh- ( 25%) rh rh 
Levine has desc ribed allother factor which because uf its reciprucal 
relationship to thc Hh factor has been dcsnibed as the Hr factor. 
Because of its pcculial' reciprucal relationship to the Hh factOl', 
thc Hr factor by its llresence ur abscncc ill thc cryt.hrucytes has 
been used to distinguish homozygous and heterozygous Rh posi-
tive blood. In this tcst cr,),throcytes frum humozyguus ilillividuais 
are not agglutinated by the anti HI' serum. 
Hecently it has becn found that the Rh factor as un antigl'1l llIay 
produce more than onc tYlle uf antibudy. This secund type of anti -
body pruduced is sometillles designated as a blocking antibudy 
which specifically unites with and coats the surface uf the Rh pusi-
tive erythrocytes without illducing physical effective aggiutillatiull. 
In other words the antibody is incomlliete becausc unly the first 
stage of the reaction occurs. The specifically coated Rh positive 
erythrocytes are now ineapablc of reacting wIth the usual anti Rh 
agglutin and as a result special tests havc been described by means 
of whi.ch it is possible to detect the anti Rh agglutin in the usual 
manner and the so-callcd blocking antibody as well. The blocking 
antibody according to Wiencr, is of more importance in the pro-
ducti.on of hemolytic disease than thc Rh antibody. The blocking 
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antibody has a smaller molecule and theoretically passes the 
placental barrier more readily, and it is strongly antigenic. 
Many examples of iso-immunization by repeated transfusions of Rh 
positive blood into Rh negative recipients are recorded in the literature. 
Levine has found a definite history of prior transfusions in sixteen of a 
series of twenty-five cases of hemolytic disease of the newborn in the first 
born of Rh negative women. Levine has further emphasized the import-
ance of small immunizing doses of blood and has calculated that only 
.13.cc. of fetal blood is required to immunize the Rh negative mother. 
As a result of these alld other observations we must assume that once 
an individual is immunized to the Rh factor, either by repeated trans-
fusions, intramuscular injection of blood or by pregnancy, he must 
be considered as immunized for the remainder of his natural life, and 
further that with each succeeding exposure to Rh positive blood he 
will probably produce increasingly greater quantities of antibody. Accord-
ingly, it is important in pediatric practice to administer only Rh negative 
blood to Rh negative female infants and to minimize the intramuscular 
injection of blood from any donor who is Rh positive. One or more trans-
fusions of Rh positive blood administered to an Rh negative female infant 
rnay prevent her many years later from having one or more normal Rh 
positive infants. Further, Rh testing is particularly indicated if repeated 
transfusions are anticipated especially in young females before and during 
t,he childbearing period, and in some, past the menopause, if they have 
borne children, particularly if there is any evidence in the history which 
would indicate previous immunization to the Rh factor. Humans, as well 
as experimental animals, differ considerably in the ease with which they 
become sensitized to various antigens. In humans this is indicated by 
the fact that approximately one out of ten marriages are of the serologic 
sequence (Rh positive male, Rh negative female) which is capable of 
producing infants with hemolytic disease. Actually only one in approxi-
mately two-hundred fifty newborns is so affected. Further, sensitization 
in pregnancy probably increases only with repeated exposures to the Rh 
factor as an antigen and as a consequence hemolytic disease in the first 
borne is relatively uncommon unless there is a history of previous expo-
sure to the Rh factor. As a rule we can anticipate one, two, or perhaps 
more perfectly normal children who may be Rh positive even though 
the subsequent children are so affected. Hemolytic disease of the newborn 
is gradually increasing in importance because of two essential factors: 
first, the diagnosis is made more readily than formerly because of in-
creased diagnostic acumen and additional criteria upon which a diagnosis 
can be based; and secondly, the lowering mortality in hemolytic disease 
because of improved methods in treatment such as prompt transfusion. 
The diagnosis of hemolytic disease of the newborn usually does not 
present much difficulty. However, there are a number of diseases which 
must be kept in mind and in the differential diagnosis we must consider 
congenital syphilis, in tra-uterine or post-partum infections of the infant, 
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ccrtain hcnlUrrhagic disease of the ncwborn, very rarely congenital mal-
formation of the bilc ducts and physiologic icterus which very frequently 
occurs in ll cwborn babies. 
If we recall t hat there arc various clinical types of hemoly t ic 
disease of the newborn, we a re in a l1Iuch better position to make t he 
proper clinical diagnosis. These forms of hemolytic disease include 
fetal hydrops which is t he most severe and has a mortality rate of 
approximately 100%, t he j aundiced form, and the jaundiced forl1l 
anemia a nd finally, t he form which is manifest simply as a hemor-
rhagic diathesis. These yarious form s a re apparently related 
genetically and etiologically . 
The evidences of hemolytic disease in the infant may be found in the 
Illother or in the infa nt. In t he parents we would expect the serologic 
sequence of an Rh positive father a nd an Rh negative mother. If the 
lIIother becomes immunized to the blood of t he fetus, there will be nil 
antibodies in her blood SeHlIl1. In somc there may possibly be a history 
of p revious transfusions especiaJly with Rh positive blood or the intra-
nluscula r inj ection of blood during infancy. During pregnancy t here may 
be evidences of hydramnios, death of the fetus and at birth there is fre-
quen t ly yello,w a mniotic fluid and enlargemen t of the placenta. The 
presence of Hh antibodies in t he mot her's blood can be possibly used in 
a limited way to predict. t he OCCUlTence of hemolytic disease in the 
infa nt . If no antibody is found or if small amounts ar e found r egularly 
the infants will usually have no evidence of hemolytic disease. If large 
amounts of antibody or small amounts of antibody a re r epeatedly found, 
the infants may develop some form of hemolytic disease. 
Early appearance of large amounts of a ntibody gcncrally indicates 
a serious prognosis for the infant. If these observations are repeat edly 
confirmed, it will a llow us to predict in advance the form and approxi-
mate severity of the hemolytic p rocess a nd as a consequence in stitute 
treatment of the infant at an earlier date. In t he infant, at birth, or 
developing soon after birth, we find a jaundice, edema, hepatomegaly and 
splenomegaly with a normoblastic picture in the blood and bon e III a ITOW 
smears. 
These evidences vary considerably with the different forms of thc 
disease mentioned above. At necropsy examinat ion we find evidences 
of a hyperplastic normoblastic bone marrow with foci of extra-medul -
lary hematopoiesis in the liver, spleen, and kidneys. Oftentimes in 
the lungs we find helllocytoblasts in the pulmonary capillaries. III 
some of the lJlore severely a ffected infants there is evidence of keru-
icterus and usually evidences of enla rgement of the liver aJl(I of the 
spleen. 
In hemolytic disease immediate transfusion with adequate uruountti 
of Rh negative blood is, at present, the treatment of choice. If Rh nega-
tive blood is used there is no hemolysis of the t ran sfu sed blood by the 
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antibody in the infant. The infant is not breast fed because of the possi-
bility of continued transfer of the Rh antibody from mother to infant 
in the breast milk. For the most part repeated small transfusions have 
been used quite successfully; however, " Tiener has recommended massive 
replacement transfusions in which the infant is bled of his blood through 
an artery and at the same time blood from a n Rh negative donor is 
given intravenously. The results of treatment by small tra nsfusioll s in 
our most recent 18 cases of hemolytic disease may be seen ill the folio\\"-
illg chart: 
HEMOI,YTIC DISEASE OF THE N :F:WJIOltN 
Cases 
Icteric 
Hydrops 
(Summary of R ecent Cases) 
No. 
16 
1 
Adm. from another hospital 1 
18 Total . 
Deaths 
2 
o 
1 
3 
This is obviously a much lower 1lI0rtality rate t han we lIligltt a n tici-
vate without the benefit of immedi ate and adequate trallsfusions. III 
16 of these 18 cases the transfusion data a re sUlllm arized Oil the accolll-
panying chart : 
INTRA-OSSEO US TltANsFUSION DATA 
(16 cases) 
Trallsfusions 
No. per case (Aver. ) 
Cc.per case (Aver.) 
56 
3.25 
188.5 
We have used the intra-osseous as well as the umbilical route ill 
our patients for convenience and ease of transfusion. For illfants ill 
whom hemolytic disease was anticipated we have been able to use the 
umbilical cord very successfully. \i\Ti t h all of these facts in llIind I would 
like to suggest the following policy ill pregllant wOlllen with r egard to 
the Rh factor. 
SUGGESTED POLICY I N PREGNAN CY 
1. All obstetric patients a re Hh typed at the tillle of first visit. 
In the Rh negative group also type husballd , other childrell, 
and if possible the parents of husballd. Do Hr typillg on 
husband if available. 
~. In all Rh negative fem ales with Rh positive husbands do anti-
RH and blocking tests at 2 week in te rvals begiuning at 24th 
week of gestation and at 1 week in tervals after 30 weeks 
gestation. 
3 . Have Rh negative blood available for immediate transfusioll 
of all infants delivered of wOlllen wit h anti Rh or blocking 
antibodies. 
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4. In all WOlllell with Rh antibodies study the infant carefully at 
birth notillg the size and weight of placenta, presence of 
hy(lramnios, wlor of amniotic fluid and repeated blood smears 
Oil infant. 
7 
If these various suggestions arc followed it is entirely probable that 
henlOlytic disease call be anticipated with some degree of certainty and 
adequate therapeutic steps carried out. I mention two more items not 
because they a re of clinical importance at this time but because they 
Ill ";'y be theoretically important at a later date. If an individual is simul-
taneously inj ected with two antigens he will react almost entirely to the 
stronger of these two antigens. As a consequence it is theoretically possi-
ble to give during early pregnancy, a strong antigen and inhibit sensiti-
zation to the Rh factor. At present we are unable to predict which 
women are susceptible to Rh sensitization. 
The seco nd observation is based on the wOl·k of Homberger who has 
found in experimental animals immunized with rhesus cells that the 
sillluitaneous administration of sodium salicylate will inhibit the produc-
tion of antibodies. It is impossible to use this drug at present because 
of the high toxicity of the drug but the observation is of illlPortance 
because it is entirely possible that other chemical agents rnay be found 
which will inhibit the production of the Rh antibodies but will not have 
the high toxicity of large doses of sodium salicylate. 
S U MMARY; 
I have reviewed the recent literatu re concerning the Rh factor allti 
its relationship to hemolytic disease of the newborn. As we study this 
problem more thoroughly we become impressed particularly with potential 
sensitization of young females by indiscriminate use of blood. It is 
probable that we should omit the use of intra-muscular blood, and Rh 
positive blood to Rh negative young female infants. 'Vhen patients come 
to us worried because of incomplete information based on popular 
accounts of this subject in lay magazines we can assure them that not 
all women become sensitized equally and hence there is a strong proba-
bility that they will never deliver an infant with hemolytic disease even 
though the serologic sequence is consistent. Further, that if they should 
develop this form of sensitivity they will probably have several normal 
children before they have one with hemolytic disease, and if the 
father is heterozygous Rh positive 50% of the children will be born as 
Hit negative infants and hence free of hemolytic disease. If the infants 
are born with hemolytic disease and especially if this is anticipated, 
immediate prompt treatment improves the prognosis immeasurably and 
will result in normal living children even though they have hemolytic 
disease in infancy. Further work can be done along the line suggested 
by double immunization and the use of chemical reagents to diminish 
the capability of forming antibodies. 
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